Clinical trials: Melanoma of Skin
Skin Cancer
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
The researcher can proved that certain compounds play an important role in the prevention of skin cancer. Researcher can use specific compounds, which classified as metabolic enzymes, and lower concentrations and complete absent…
- Trial name
- NCT02244749
- Testing
- skin specimen
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of California, Irvine
Melanoma (Skin)
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602576
- Testing
- sorafenib tosylate, temozolomide
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma (Skin)
Irofulven in Treating Patients With Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have stage IV…
- Trial name
- NCT00005968
- Testing
- irofulven
- Where
- 5 sites in United States
- Sponsor
- University of Colorado, Denver
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Melanoma
Timing of Immunotherapy in Melanoma
The TIME-NL trial is a multicenter, randomized, open-label clinical trial in the Netherlands to assess the effect of the timing of the first administration of standard-of-care intravenous combination immunotherapy (early morning…
- Trial name
- TIME-NL (NCT07696715)
- Testing
- Timing of first administration (early morning), Timing of immunotherapy (afternoon)
- Where
- 5 sites in Netherlands
- Volunteers
- 170 people
- Sponsor
- Radboud University Medical Center
Cutaneous Melanoma, Stage II, Malignant Cutaneous Melanoma
Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma
Malignant melanoma, responsible for 75% of deaths from skin cancer. Current therapeutic options have poor response, many adverse events and high costs.
- Conditions
- Cutaneous Melanoma, Stage II, Malignant Cutaneous Melanoma, Cutaneous Melanoma, Stage III
- Trial name
- NCT03541148
- Testing
- Oncoxin-Viusid
- Where
- Cuba
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Catalysis SL
Solid Tumor
A Study of ASP1012 in Adults With Solid Tumors
ASP1012 is a type of virus called an oncolytic virus which is used to treat some cancers. ASP1012 was changed in a laboratory to infect and kill cancer cells, leaving healthy cells alone.
- Trial name
- NCT06171178
- Testing
- ASP1012, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Melanoma (Skin Cancer), Nevi and Melanomas
Precision Medicine for L/GCMN and Melanoma 2
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of…
- Conditions
- Melanoma (Skin Cancer), Nevi and Melanomas, Congenital Melanocytic Nevus
- Trial name
- Precis-mel 2 (NCT06605443)
- Testing
- Breath analyzer, Skin patch, Liquid biopsy
- Where
- 3 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Melanoma
Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma
Rationale: Ipilimumab, a monoclonal antibody targeting CTLA-4, is approved for the treatment of metastatic melanoma and significantly increases median overall survival.
- Trial name
- Zirconipi (NCT03313323)
- Testing
- 89Zirconium-labeled ipilimumab
- Where
- Netherlands
- Volunteers
- 29 people
- Sponsor
- Amsterdam UMC, location VUmc
Melanoma
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
This study is being conducted to explore the efficacy and safety of SHR-1701 combined with temozolomide in the treatment of advanced melanoma.
- Trial name
- NCT05106023
- Testing
- SHR-1701, Temozolomide
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Yong Chen
Melanoma, Squamous Cell Lung Cancer
Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)
This is a multicenter, non-interventional, retrospective study (with two prospective cohorts), including previously treated patients with melanoma, squamous cell lung cancer in the late stages (inoperable or metastatic) and…
- Conditions
- Melanoma, Squamous Cell Lung Cancer, Uveal Melanoma, Hodgkin Lymphoma
- Trial name
- ICIPRESIST19 (NCT04025424)
- Testing
- Genetic tests of the available tumor and plasma samples
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- Russian Academy of Medical Sciences
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes.
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Trial name
- NCT04221438
- Testing
- Binimetinib, Conventional Surgery, Encorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Head and Neck Cancer, Melanoma
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient…
- Conditions
- Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma
- Trial name
- NCT05061940
- Testing
- Tumor Profiling
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Repertoire Immune Medicines
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Lung Neoplasm, Lymphoma
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
To determine the minimum scan duration for fluorine-18 positron-emitting radioactive isotope-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) scans performed on a total-body PET/CT scanner…
- Conditions
- Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose
- Trial name
- NCT04478318
- Testing
- uEXPLORER/mCT, mCT/uEXPLORER
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of California, Davis
Melanoma, In-Transit Metastasis of Cutaneous Melanoma
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
There is currently an urgent need for low cost and well tolerated intralesional agents for the management of in transit and cutaneous melanoma metastases that are unsuitable for, or resistant to, other therapies.
- Trial name
- INTRANS (NCT03754140)
- Testing
- Polidocanol Injection
- Where
- Australia
- Sponsor
- Melanoma Institute Australia
Metastatic Melanoma
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
This is a Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in subjects who have metastatic melanoma which has advanced beyond the point at which local therapies such as surgery or radiation therapy would be…
- Trial name
- NCT00256282
- Testing
- Vinorelbine, Docetaxel, Sargramostim
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- John P. Fruehauf
Malignant Melanoma
A Study of Vemurafenib in Participants With Metastatic Melanoma
This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer [AJCC])…
- Trial name
- NCT01307397
- Testing
- Vemurafenib
- Where
- 280 sites in Albania, Argentina and 42 more
- Volunteers
- 3,219 people
- Sponsor
- Hoffmann-La Roche
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Cancer, Metastatic Melanoma
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
This study will explore the ability of patients on first line combination immunotherapy to sample cytokines at home. The data from this study will be used to evaluate the feasibility of in-home testing and the ability to analyse…
- Conditions
- Cancer, Metastatic Melanoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT04960059
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- The Christie NHS Foundation Trust